A CLINICAL EVALUATION OF MARMAGULIKA LEPAM (MG LEPAM) IN THE MANAGEMENT OF ACUTE PAIN AND INFLAMMATION IN MUSCULOSKELETAL DISORDERS: AN OPEN-LABEL INTERVENTIONAL STUDY

Abstract

Background

Musculoskeletal disorders cause significant pain and functional limitation. NSAIDs, though effective, are associated with adverse effects, necessitating safer alternatives.

Objective

To assess the efficacy of Marmagulika Lepam (MG Lepam), an Ayurvedic external formulation, in inflammatory joint conditions.

Results

In this open-label study, 20 patients with acute or chronic joint inflammation received topical MG Lepam for 2–7 days. Pain (VAS), swelling, and tenderness were assessed before and after treatment. Mean VAS pain scores significantly reduced from 7.35 ± 1.27 to 2.38 ± 1.12 (p < 0.001). Swelling decreased from 2.45 ± 0.60 to 0.45 ± 0.51 (p < 0.001), and tenderness from 2.50 ± 0.51 to 0.25 ± 0.55 (p < 0.001).

Discussion

MG Lepam demonstrated rapid anti-inflammatory and analgesic effects, offering symptomatic relief without systemic drug exposure.

Conclusion

Marmagulika Lepam is effective in reducing pain and inflammation in joint disorders and may serve as a safe natural alternative for musculoskeletal conditions.